{"text": "In the trial , 361 subjects were randomized into three parallel treatment arms and treated for 12 weeks .Daily urinary incontinent episodes decreased by 42 % in the placebo group , compared to 62 % in the transdermal oxybutynin group and 64 % in the Detrol LA group .", "label": "", "metadata": {}, "score": "29.815636"}
{"text": "The randomized , double - blind , placebo - controlled , parallel - group clinical study enrolled 470 subjects , aged 12 years and older , who received Qnaze nasal aerosol 320 mcg or placebo once - daily for six weeks .", "label": "", "metadata": {}, "score": "34.26148"}
{"text": "This six - month , open label trial enrolled 13 pediatrics , ages five to 12 years , with rickets and gross motor deficits from HPP .", "label": "", "metadata": {}, "score": "34.774765"}
{"text": "This randomized , double - blind , placebo - controlled study enrolled 45 patients at 2 sites , who received an injection of the drug or placebo , prior to treatment with a local anesthetic .", "label": "", "metadata": {}, "score": "36.002365"}
{"text": "Sample size was determined to detect a 40 % difference in the occurrence of grade 1 - 4 ( World Health Organization [ WHO ] scale ) neurotoxicity between the two treatment arms .", "label": "", "metadata": {}, "score": "37.645676"}
{"text": "Of these , 9 ( 3 % ) were ineligible , 1 ( 0.4 % ) was unable to give consent , and 36 ( 13 % ) refused to give consent ; 2 psychiatrists each withdrew a referral ( 1 % ) .", "label": "", "metadata": {}, "score": "38.423943"}
{"text": "Study Design : .The study had a randomized , placebo - controlled , clinical trial with parallel group design .Measurement Instruments / Methods : .", "label": "", "metadata": {}, "score": "38.852074"}
{"text": "Significant efficacy variance was noted between investigative sites ( range of improvement : 7.6%-73.3 % ) , based primarily on differences in injection technique .This randomized , double blind , placebo - controlled parallel arm study enrolled two study cohorts of 100 patients each across 5 US sites .", "label": "", "metadata": {}, "score": "38.99927"}
{"text": "This parallel dose study enrolled 48 healthy volunteers , who received daily topical applications of one of 3 doses of the drug over 20 days .", "label": "", "metadata": {}, "score": "39.16949"}
{"text": "These 2 groups were similar at baseline in terms of demographic and clinical characteristics ( Table 1 ) .Before randomization , FGAs were being prescribed to 207 patients and SGAs to 44 .", "label": "", "metadata": {}, "score": "39.42021"}
{"text": "Less than 2 % of subjects in any dosing group withdrew from the study after 12 weeks due to changes in kidney function .This randomized , double - blind study enrolled 453 patients with severe plaque psoriasis across 32 sites in Canada .", "label": "", "metadata": {}, "score": "40.263016"}
{"text": "Intervention Characteristics / Basic Study Process : .151 women with advanced ovarian cancer were randomized to receive cisplatin with or without GSH 3 g / m\u00b2 in 200 cc of normal saline or cisplatin and a placebo - infusion of 200 cc of normal saline administered over 20 minutes immediately before cisplatin administration .", "label": "", "metadata": {}, "score": "40.92817"}
{"text": "This randomized , double - blind , placebo - controlled study enrolled 38,546 adults with no history of shingles , who received a single - dose of the vaccine or placebo and were then followed for 3.12 years .", "label": "", "metadata": {}, "score": "41.364998"}
{"text": "Four of 10 centers measured quality of life with the Hospital Anxiety and Depression Scale .Anemia , leukopenia , thrombocytopenia , neurohearing , nephrotoxicity , peripheral neuropathy , and nausea and vomiting were assessed using the National Cancer Institute 's Common Terminology Criteria for Adverse Events and World Health Organization toxicity scales .", "label": "", "metadata": {}, "score": "41.693504"}
{"text": "The trial enrolled 48 subjects , aged 9 to 17 years , with genetically confirmed FRDA .The subjects received placebo or one of three doses of SNT - MC17 .", "label": "", "metadata": {}, "score": "42.556206"}
{"text": "This placebo - controlled follow - up treated 20 HLA - DR2 or HLA - DR4 patients , who received 500 mg MBP8298 or placebo every 6 months .", "label": "", "metadata": {}, "score": "43.258698"}
{"text": "At nine weeks , no patients who received GSH had clinical evidence of neuropathy , compared to16 patients ( 66 % ) in the placebo - control group .", "label": "", "metadata": {}, "score": "43.275917"}
{"text": "Seventy - seven women received the placebo infusion and 74 received GSH .Sample Characteristics : .151 women with ovarian cancer .Setting : .", "label": "", "metadata": {}, "score": "44.091263"}
{"text": "Six of eight subjects ( 75 % ) with thrombocytopenia experienced a more than 50 % increase in their platelet count .The most commonly reported adverse events were constipation , leukocytosis , mild neuropathy and mild sedation .", "label": "", "metadata": {}, "score": "44.610283"}
{"text": "The study had a randomized , double - blind , placebo - controlled trial design .Measurement Instruments / Methods : .A neurologic examination , including measures of strength and reflexes , assessment of neurologic symptoms , position and vibratory sensation , and neurophysiologic evaluations of sural nerves were conducted at baseline , 4 , 8 , and 12 cycles of chemotherapy .", "label": "", "metadata": {}, "score": "44.638615"}
{"text": "Twenty - eight ( 48 % ) of the 58 patients randomized to the FGA arm and prescribed sulpiride were still taking that drug at the end of the study , although 3 were receiving another antipsychotic drug in addition .", "label": "", "metadata": {}, "score": "45.022617"}
{"text": "Only 18 patients received 12 cycles of chemotherapy , 10 in the GSH arm and 8 in the placebo arm .Grade 2 - 3 neurotoxicity was observed in three patients in GSH arm and eight patients in the placebo arm .", "label": "", "metadata": {}, "score": "45.56765"}
{"text": "One patient was prescribed clozapine immediately before randomization .Twenty - eight patients ( 12 % ) were receiving more than 1 antipsychotic drug before randomization ; 13 ( 11 % ) of these were randomized to the FGA arm and 15 ( 14 % ) to the SGA arm ( Table 1 ) .", "label": "", "metadata": {}, "score": "45.678947"}
{"text": "Follow - up assessments were performed blinded to randomized allocation at 12 , 26 , and 52 weeks .Telephone interviews were performed on a few occasions .", "label": "", "metadata": {}, "score": "46.847878"}
{"text": "Results : .Seven patients in the placebo group were unable to complete the study ( six with progressive disease and one from grade 3 neurotoxicity ) .", "label": "", "metadata": {}, "score": "47.21008"}
{"text": "This open label extension evaluated a total of 493 women with recurrent SUI , all of whom had participated in the initial single - blind , placebo controlled phase III study .", "label": "", "metadata": {}, "score": "47.3813"}
{"text": "This open - label extension study enrolled all 38 patients who had completed the initial 24 week trial ; all patients received 1.0 mg / kg Aryplase via weekly infusion .", "label": "", "metadata": {}, "score": "48.407417"}
{"text": "This randomized , double - blind , controlled study enrolled 396 patients across 25 US sites , who received the drug , approved treatment with beclomethasone , or placebo twice daily for 7 days .", "label": "", "metadata": {}, "score": "49.0028"}
{"text": "The primary objective of the study was reached .Daily treatment of a 1 g dose ( approximately 1 mL ) of oxybutynin topical gel for 12 weeks was superior to placebo for the relief of OAB symptoms .", "label": "", "metadata": {}, "score": "49.111427"}
{"text": "Trial data met their primary safety endpoint , with no serious adverse events reported and positive local and systemic adverse event profiles .Pharmacokinetic data did not indicate systemic exposure 48 hours post treatment in the highest dosing group .", "label": "", "metadata": {}, "score": "49.289062"}
{"text": "The trial was funded by the Health Technology Assessment Program of the United Kingdom National Health Service and received no financial support from the pharmaceutical industry .", "label": "", "metadata": {}, "score": "49.85305"}
{"text": "The subjects were divided among five groups and self - administered one of four concentrations of V-101 cream or placebo cream once daily for 28 days .", "label": "", "metadata": {}, "score": "50.110367"}
{"text": "Further analysis was performed using Stata Version 7 ( StataCorp , College Station , Tex ) .Longitudinal analysis of covariance ( ANCOVA ) was used to estimate the differences between the treatment arms in QLS total scores at each of the 3 assessments ( 12 , 26 , and 52 weeks ) , using study center and baseline QLS score as covariates .", "label": "", "metadata": {}, "score": "50.40679"}
{"text": "Safety and efficacy assessments were performed at weeks one , three , six , and nine .The primary efficacy endpoint was mean percent reduction in the number of inflammatory lesions from Baseline to Week 9 .", "label": "", "metadata": {}, "score": "50.89"}
{"text": "This randomized , double - blind , parallel , placebo controlled , multi - center trial enrolled 600 subjects who received two dose strengths of Anturol ( 56 mg or 84 mg ) administered topically once daily ( QD ) or placebo for 12 weeks .", "label": "", "metadata": {}, "score": "51.24884"}
{"text": "At the nine month follow - up time point , statistically significant suppression of the bone biomarker CTX-1 was noted .Following a single dose of 1mg / kg , 4 out of 6 subjects ( 67 % ) , in this highest dose group , showed statistically significant suppression of CTX-1 at 9 months .", "label": "", "metadata": {}, "score": "51.84722"}
{"text": "Patients were treated with either 2.5\u03bcg / kg / daily , 7.5\u03bcg / kg/ daily or 15\u03bcg / kg/ daily .A total of 26 children with achondroplasia with an average age of 7.8 years were enrolled .", "label": "", "metadata": {}, "score": "51.911552"}
{"text": "The subjects were equally randomized to one of three treatment arms : 200 mg or 400 mg FV-100 administered once daily or 1,000 mg valacyclovir ( standard of care ) administered three times per day .", "label": "", "metadata": {}, "score": "51.97998"}
{"text": "Nine of 13 subjects enrolled ( 69 % ) and nine of 12 who completed the study ( 75 % ) achieved a substantial improvement in rickets as assessed by skeletal radiographs of the wrists and knees , compared with two of 17 ( 12 % ) historical controls .", "label": "", "metadata": {}, "score": "52.65373"}
{"text": "Disease response was assessed after four cycles of therapy .Those with responsive or stable disease received four additional cycles of treatment .Sample Characteristics : .", "label": "", "metadata": {}, "score": "52.792362"}
{"text": "The average period from randomization to initiation of the assigned drug was 8.5 days ( median , 1 day ) .There were 3 deaths in each arm .", "label": "", "metadata": {}, "score": "52.903214"}
{"text": "The subjects were randomly assigned to treatment with Botox or placebo injections into the detrusor ( bladder ) muscle , followed by an injection with Botox after a minimum of 12 weeks if desired .", "label": "", "metadata": {}, "score": "53.00983"}
{"text": "In a study by Rosenheck and colleagues , 36 309 patients were randomized to receive olanzapine , an SGA , and the classic FGA haloperidol , with flexible dosing and the use of prophylactic anticholinergic drugs .", "label": "", "metadata": {}, "score": "53.33396"}
{"text": "In the second trial , the mean pre - treatment B-12 levels for the PreHistin and placebo groups , respectively , were 581.58 and 508.54 and the mean post - treatment B-12 levels were 1938.31 and 514.70 , for a 233.28 % versus a 1.21 % change .", "label": "", "metadata": {}, "score": "53.357086"}
{"text": "Pain intensity was recorded daily by the subjects for 12 weeks , using the Numeric Pain Rating Scale .NeurogesX plans to submit a MAA to the EMEA in early 2007 and a NDA to the FDA in mid-2008 .", "label": "", "metadata": {}, "score": "53.441544"}
{"text": "Among subjects with 18 or more lesions at Baseline , the mean reduction for once - daily omiganan 2.5 % was 40 % , compared to an 11 % lesion increase in the once - daily placebo group .", "label": "", "metadata": {}, "score": "53.496643"}
{"text": "The primary outcome was the total score on the Quality of Life Scale ( QLS ) , 11 an instrument used widely in psychopharmacologic treatment trials for schizophrenia , 12 , 13 assessed blindly at baseline and 12 , 26 , and 52 weeks .", "label": "", "metadata": {}, "score": "53.616653"}
{"text": "Journal of Clinical Oncology , 13 , 26 - 32 .Intervention Characteristics / Basic Study Process : .Fifty patients with advanced gastric cancer were randomized to receive either 1.5 g / m\u00b2 GSH in 1 L of normal saline or normal saline 1 L as a placebo infusion given over 15 minutes before cisplatin - based chemotherapy .", "label": "", "metadata": {}, "score": "53.860207"}
{"text": "However , the TNSS data for placebo - treated subjects was far lower than would be expected for this population .The very low symptom levels reported in both the placebo and PreHistin groups were determined to be likely due to low pollen counts in the regions where the trials were conducted .", "label": "", "metadata": {}, "score": "53.930573"}
{"text": "Efficacy and adverse events were evaluated at baseline and at weeks four , eight , twelve and sixteen .The objective of the study was to demonstrate that increasing the dose of doxycycline above the anti - inflammatory levels provided by Oracea does not provide any additional benefit but significantly adds to the adverse event profile .", "label": "", "metadata": {}, "score": "55.67002"}
{"text": "This trial was independent of industry , being funded by the National Health Service .This organization also has interests in treatment costs , although its Health Technology Assessment Program is charged with providing objective evidence on interventions .", "label": "", "metadata": {}, "score": "55.71366"}
{"text": "Based on these results , the company announced plans to initiate a multiple - dose phase II study of the drug in the near future .", "label": "", "metadata": {}, "score": "55.75855"}
{"text": "The addition of GSH to cisplatin chemotherapy allowed the full six cycles to be administered to more patients ( 58 % ) as compared to those who received cisplatin alone ( 39 % ) .", "label": "", "metadata": {}, "score": "55.822613"}
{"text": "The study was performed on patients who had received preliminary date on a small number of patients with no true control group .Cascinu , S. , Cordella , L. , Del Ferro , E. , Fronzoni , M. , & Catalana , G. ( 1995 ) .", "label": "", "metadata": {}, "score": "55.882645"}
{"text": "Intervention Characteristics / Basic Study Process : .Fifty - two patients with advanced colorectal cancer who were treated with a bimonthly oxaliplatin - based regimen were randomized to receive glutathione ( GSH ) ( 1,500 mg / m\u00b2 over a 15-minute infusion period before oxaliplatin ) or normal saline solution .", "label": "", "metadata": {}, "score": "56.060265"}
{"text": "Full 24 week data was expected during the first half of 2006 .August 1 , 2005 .CollaGenex has announced positive results of a pair of phase III trials of Oracea , for the treatment of rosacea , at the summer meeting of the American Academy of Dermatology .", "label": "", "metadata": {}, "score": "56.184753"}
{"text": "Figure 1 shows the patients ' subsequent progress through the trial .One protocol violation , a patient randomized before the referring psychiatrist reformulated the diagnosis , was included in the final analysis in his or her randomized treatment arm .", "label": "", "metadata": {}, "score": "56.332375"}
{"text": "Multiple imputations for this second model of QLS involved the generation of 5 full data sets using the propensity score method in Solas version 3.2 , each of which was then analyzed as described previously herein ( combining the results as suggested by Rubin and Schenker 23 ) .", "label": "", "metadata": {}, "score": "56.50098"}
{"text": "Finally , we have to consider the participants : patients , psychiatrists , and researchers .Regarding the study sample , PANSS total and other scores were similar at baseline to those of other treatment trials in schizophrenia .", "label": "", "metadata": {}, "score": "56.55496"}
{"text": "First , a conventional ITT analysis was performed using ANCOVA as previously described but restricting the outcome to 12-week scores .Then , in a per - protocol analysis , participants who switched from their allocated arm before the 12-week follow - up were dropped and the ANCOVA was repeated .", "label": "", "metadata": {}, "score": "56.795853"}
{"text": "Dr. Anzai found only 33 % of patients had CT evidence of acute sinusitis which reflects an over - diagnosis of acute sinusitis in the primary care setting .", "label": "", "metadata": {}, "score": "57.062218"}
{"text": "One cycle consisted of nine weekly treatments .Patients who showed responsive or stable disease received an additional six weeks of therapy .Sample Characteristics : .", "label": "", "metadata": {}, "score": "57.10033"}
{"text": "The trial included an economic component and was called the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study ( CUtLASS 1 ) .Participants were randomized to receive either an FGA or an SGA .", "label": "", "metadata": {}, "score": "57.24188"}
{"text": "Subjects had experienced at least seven episodes of incontinence per week .Results were published in September 2003 in the Journal of Urology .July 29 , 2002 .", "label": "", "metadata": {}, "score": "57.493164"}
{"text": "The decision to use depot preparations at randomization was not common ( 12 in the FGA arm ) compared with previous treatment .Similar numbers of patients in each arm were being treated with depot FGAs at 1 year ( 18 in the FGA arm and 17 in the SGA arm ) .", "label": "", "metadata": {}, "score": "57.624996"}
{"text": "Overall , the patients had fairly long - term illness , and treatment effects were not large .The results may have been clearer in subgroups of patients with certain clinical features or shorter duration of illness , for example .", "label": "", "metadata": {}, "score": "58.311478"}
{"text": "Measurements in the changes in the number of inflammatory lesions were taken at weeks 4 , 8 , 12 and 16 .The primary endpoint was the mean number of changes at week 12 and 16 .", "label": "", "metadata": {}, "score": "58.428146"}
{"text": "Each subject received XEN - D0501 ( 1 , 2.5 or 5 mg ) or placebo twice daily for 13 days .Part 2 was an open - label , randomized , two - way crossover study in subjects aged 45 to 65 years who received single doses of 5 mg XEN - D0501 under fasted and fed conditions .", "label": "", "metadata": {}, "score": "58.437645"}
{"text": "The randomized clinical trial proposed here would provide the level of evidence needed to formulate ART guidelines specific to HNCI .Subjects eligible for this trial will be individuals with HNCI who anticipate initiation of a new ARV regimen or substitution of their existing regimen following contemporary treatment guidelines .", "label": "", "metadata": {}, "score": "58.62632"}
{"text": "There were no differences in significant adverse events between the treatment arms .October 23 , 2006 .NeurogesX reported positive results from a phase III trial of Transacin for the treatment of post - herpetic neuralgia .", "label": "", "metadata": {}, "score": "58.657234"}
{"text": "Statistical significance was observed from week four with success in 49 ( 10.9 % ) and 13 ( 5.6 % ) patients for ivermectin 1 % and vehicle , respectively .", "label": "", "metadata": {}, "score": "58.74682"}
{"text": "October 22 , 2007 .Cutanea Life Sciences issued positive results from a phase II trial of omiganon for the treatment of rosacea .This randomized , placebo - controlled , double - blind , multi - center trial enrolled 240 subjects with papulopustular rosacea in the US .", "label": "", "metadata": {}, "score": "58.91385"}
{"text": "In the SGA arm , 2 deaths were also due to cardiac failure and 1 to septicemia ( in a quadriplegic patient ) .Eleven patients ( 5 % ) were categorized as lost to follow - up at 1 year , and 22 ( 10 % ) withdrew from the study .", "label": "", "metadata": {}, "score": "58.92173"}
{"text": "CollaGenex reported positive results from a phase IV trial of Oracea for the treatment of rosacea .This prospectively randomized , double - blinded , placebo - controlled clinical study enrolled ninety one subjects in the US .", "label": "", "metadata": {}, "score": "58.935066"}
{"text": "The subjects received CNTO1275 administered subcutaneously or placebo .In the CNTO1275 arm , the subjects received 45 mg or 90 mg doses at weeks 0 and 4 followed by the same dose every 12 weeks .", "label": "", "metadata": {}, "score": "58.98608"}
{"text": "After stratifying by treatment center , the method of allocation was randomized , permuted blocks within strata .Participants were recruited over 30 months from July 12 , 1999 , to January 18 , 2002 .", "label": "", "metadata": {}, "score": "59.134396"}
{"text": "Many psychiatrists who took part in the trial were , inevitably , particularly interested in schizophrenia management , and their ability to individualize treatments within the randomized arms may have minimized rather than emphasized differences in outcome .", "label": "", "metadata": {}, "score": "59.83625"}
{"text": "February 19 , 2002 .Preliminary phase IIIb trial results indicate that treatment with Watson Pharmaceuticals ' transdermal oxybutynin significantly reduces incontinent episodes compared to placebo .", "label": "", "metadata": {}, "score": "59.91591"}
{"text": "The primary outcome , change in global neuropsychological ( NP ) performance , will be assessed at 16 weeks .CNS - T will comprise two components : 1 ) initial selection of agents to optimize CNS penetration of the overall regimen ; and 2 ) modification of the regimen if an interim pharmacokinetic ( PK ) assessment determines that plasma ARV exposure is not appropriate ( overdosing , underdosing ) .", "label": "", "metadata": {}, "score": "60.012085"}
{"text": "Study Design : .The study had a randomized , placebo - controlled clinical trial design .Measurement Instruments / Methods : .Complete neurologic examination ( strength , deep tendon reflexes , symptoms of peripheral nervous system involvement , position , and vibratory sensation ) ; neurophysiologic assessment of the medial , ulnar ; and sural nerves also were performed .", "label": "", "metadata": {}, "score": "60.28813"}
{"text": "This open- label trial enrolled 18 patients with infant- onset Pompe disease , who began receiving the drug by 6 months of age .The company announced that primary efficacy results were expected during summer 2005 , when subjects will have completed 52 months of therapy .", "label": "", "metadata": {}, "score": "60.439194"}
{"text": "This was predicated on a common standard deviation of 18 for baseline and 52-week QLS scores and underpinned the primary hypothesis of an advantage for SGAs .", "label": "", "metadata": {}, "score": "60.44763"}
{"text": "December 5 , 2011 .Provesica reported results from a phase I trial of XEN - D0501 for the treatment of overactive bladder .The trial was conducted in two parts .", "label": "", "metadata": {}, "score": "60.56446"}
{"text": "Five medical schools in England were recruited , covering 14 National Health Service Trusts in northwestern England , Nottingham , western London , southeastern London , and Cambridge .", "label": "", "metadata": {}, "score": "60.68383"}
{"text": "At baseline , no patients suffered from clinical neuropathy in either arm .At the time of second the neurologic exam ( four cycles ) seven patients had clinical neuropathy in the GSH arm and 11 in the placebo arm .", "label": "", "metadata": {}, "score": "60.866257"}
{"text": "Statistical precision was limited , but the ITT analysis indicated that true effects may have been in the opposite direction for this primary outcome and for the main symptom assessments .", "label": "", "metadata": {}, "score": "60.882156"}
{"text": "An initial assessment of interrater reliability ( for 9 trained raters ) yielded an intraclass correlation coefficient of 0.91 for the QLS total score and 0.75 for the PANSS total score .", "label": "", "metadata": {}, "score": "60.9542"}
{"text": "This double - blinded , placebo - controlled , multi - center study enrolled 94 patients with a history of herpes zoster ( shingles ) followed by persistent pain due to PHN .", "label": "", "metadata": {}, "score": "61.130917"}
{"text": "The double - masked trial , which included 31 subjects , compared 4 % topical alicaforsen cream to placebo .Fifteen subjects in the trial applied treatment once per day , while 16 applied twice per day .", "label": "", "metadata": {}, "score": "61.2491"}
{"text": "Treatment arm differences for nonlongitudinal , secondary , binary outcome measures were evaluated using Pearson \u03c7 2 .Treatment arm differences in ordinal outcomes ( eg , patient satisfaction ) were evaluated using the Mann - Whitney test .", "label": "", "metadata": {}, "score": "61.272488"}
{"text": "Of enrolled subjects , 213 and 104 subjects were treated with Androxal and placebo , respectively .The study results showed no evidence of a negative effect on bone mineral density in subjects treated with Androxal in comparison to the placebo treatment group .", "label": "", "metadata": {}, "score": "61.355293"}
{"text": "February 12 , 2007 .CollaGenex reported positive results from a phase IV trial of Oracea plus topical MetroGel for the treatment of rosacea .This double - blind , placebo - controlled trial enrolled a total of 72 rosacea subjects who received either Oracea capsules plus MetroGel or placebo capsules plus MetroGel once a day for 12 weeks .", "label": "", "metadata": {}, "score": "61.376415"}
{"text": "July 16 , 2007 .Cobalis released mixed results from two phase III trials of PreHistin for the treatment of seasonal allergic rhinitis .These parallel , randomized , double - blind trials enrolled 1,551 subjects in the US .", "label": "", "metadata": {}, "score": "61.469307"}
{"text": "Following an additional dose at week 16 , responses were maintained through week 28 .Treatment was well tolerated , with adverse events comparable between the CNTO1275 and placebo groups .", "label": "", "metadata": {}, "score": "61.526165"}
{"text": "Celgene reported positive results from a phase II trial investigating Thalomid ( thalidomide ) in combination with prednisone for the treatment of myelofibrosis .The data demonstrated that 13 of 21 subjects ( 62 % ) achieved an objective clinical response that was defined by an increase in red blood cells or platelets .", "label": "", "metadata": {}, "score": "61.645927"}
{"text": "Based on the safety profile observed to date across the three dose cohorts , all subjects have been switched to the highest dose of 15\u03bcg / kg/ daily for the duration of the 18 month extension study .", "label": "", "metadata": {}, "score": "61.674316"}
{"text": "Subjects recorded pain intensity twice daily on an 11-point numerical scale .The double blind , randomized controlled , multi - center study evaluated the tolerability , safety and efficacy of NGX-401 in the treatment of postherpetic neuralgia .", "label": "", "metadata": {}, "score": "61.678215"}
{"text": "London , England National Institute for Clinical Excellence2002 ; .Rosenheck RCramer JXu WThomas JHenderson WFrisman LFye CCharney DDepartment of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia , A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia .", "label": "", "metadata": {}, "score": "61.707893"}
{"text": "London , England National Institute for Clinical Excellence2002 ; .Rosenheck RCramer JXu WThomas JHenderson WFrisman LFye CCharney DDepartment of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia , A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia .", "label": "", "metadata": {}, "score": "61.707893"}
{"text": "Transepidermal water loss measurements showed a 22 % decrease in water loss , which supports an improvement in skin barrier function .Based on these results , Senetek extended this study to 48 weeks .", "label": "", "metadata": {}, "score": "61.739727"}
{"text": "12 One of several quality - of - life measures in the Veterans Affairs Cooperative Study in Health Services No .17 comparing clozapine and haloperidol in refractory schizophrenia , 26 the QLS was sensitive to subtle change and treatment effect .", "label": "", "metadata": {}, "score": "61.761826"}
{"text": "At 12 weeks , mean PASI score improvements were 14 % for the 1 mg / kg Xanelim group and 13 % for the 2 mg / kg group , compared to 8 % for placebo - treated subjects .", "label": "", "metadata": {}, "score": "61.839226"}
{"text": "Clinical equipoise shifted in favor of SGAs during the trial , pressurizing recruitment .However , good follow - up and a close correlation between QLS score at baseline and follow - up meant that the recruited sample gave 75 % power to detect the hypothesized difference in QLS scores .", "label": "", "metadata": {}, "score": "61.841614"}
{"text": "December 5 , 2005 .Rigel Pharmaceuticals issued negative results of a phase II study of R112 , for the treatment of allergic rhinitis .Trial data failed to meet their primary endpoint , producing no significant reduction in symptom severity score on the total nasal symptom severity diagnostic scale , compared to placebo .", "label": "", "metadata": {}, "score": "62.095848"}
{"text": "Neuroprotective effect of reduced glutathione on oxaliplatin - based chemotherapy in advanced colorectal cancer : A randomized , double - blind , placebo - controlled trial .", "label": "", "metadata": {}, "score": "62.122017"}
{"text": "Nymox announced safety results of a phase II trial of NX-1207 , for the treatment of benign prostatic hyperplasia ( BPH ) .Results from the ongoing study to date yielded no serious drug - related adverse events .", "label": "", "metadata": {}, "score": "62.16994"}
{"text": "The most frequently reported adverse events were injection site reactions , dizziness and headache .No serious adverse events were reported .The multi - center , double - blind , randomized , placebo - controlled escalating single dose study is enrolling up to 5 subjects with ALS .", "label": "", "metadata": {}, "score": "62.80619"}
{"text": "Results showed that subjects treated with INS37217 Intranasal demonstrated statistically significant improvement in PAR symptoms as compared to placebo across multiple days and multiple doses .", "label": "", "metadata": {}, "score": "62.83557"}
{"text": "February 2012 ( final data collection date for primary outcome measure ) .Eligibility Criteria ICMJE .Under consideration to initiate or change their HAART regimens ( based on current consensus treatment guidelines ) as directed by their primary care physicians .", "label": "", "metadata": {}, "score": "62.855198"}
{"text": "The sum of the mean scores from each area yields a total score .The QLS takes approximately 45 minutes to complete ; interrater reliabilities are high , and confirmatory factor analysis has been conducted .", "label": "", "metadata": {}, "score": "62.892616"}
{"text": "The open - label study enrolled 10 subjects with MPS VI and was conducted at two sites in the U.S. and one in Australia .The study evaluated clinical and biochemical measures of saftey and efficacy of Aryplase in subjects aged 6 to 22 for 22 weeks .", "label": "", "metadata": {}, "score": "62.909584"}
{"text": "The trial enrolled 17 patients with a mean BMI of 31.4kg / m2 and mean BW of 71.8 kg .Results showed beloranib appeared safe and well - tolerated , and led to dose - dependent body and total fat mass reductions despite a 50 % increase in total daily calorie intake .", "label": "", "metadata": {}, "score": "62.97673"}
{"text": "August 13 , 2007 .Cobalis announced additional positive results from a phase III trial of PreHistin for the treatment of seasonal allergic rhinitis .These parallel , randomized , double - blind trials enrolled 1,551 subjects in the US .", "label": "", "metadata": {}, "score": "63.133255"}
{"text": "These data were sufficiently positive for the trials Independent Data Monitoring Committee to recommend continuation of the study , with no modifications to the trial 's design .", "label": "", "metadata": {}, "score": "63.240814"}
{"text": "Benefits in terms of a reduction in observed akathisia and improved cognition were weighed against the problems of weight gain and higher costs .Lieberman and colleagues 37 reported an 18-month double - blind trial in which 1493 patients with chronic schizophrenia were randomized to receive olanzapine , quetiapine , risperidone , ziprasidone , or perphenazine , a low - potency FGA .", "label": "", "metadata": {}, "score": "63.274635"}
{"text": "Subjects received either eteplirsen 30mg / kg or 50mg / kg once weekly for 48 weeks , or for 24 weeks followed by another 24 weeks of placebo .", "label": "", "metadata": {}, "score": "63.523575"}
{"text": "Nevertheless , the choice of the QLS deserves scrutiny .A good quality - of - life scale should be appropriate to the study population , the clinical condition , and the illness phase ; have established psychometric properties ; and measure several dimensions .", "label": "", "metadata": {}, "score": "63.726917"}
{"text": "Treatment was determined to be safe and well tolerated .Based on the results Allergy Therapeutics plans to file an MAA in the EU in quarter one of 2009 .", "label": "", "metadata": {}, "score": "63.73645"}
{"text": "This suggests that the present trial design was sensitive enough to show the effect we hypothesized , had it been present .Although we note the considerable pharmacologic heterogeneity within and between the FGA and SGA groups , we consider the comparison between groups to have been clinically useful .", "label": "", "metadata": {}, "score": "63.95228"}
{"text": "The outcome measure is change in performance from baseline to 16 weeks as measured by the global deficit score ( GDS ) .The GDS is calculated by averaging the individual deficit scores from each neurocognitive test .", "label": "", "metadata": {}, "score": "64.33569"}
{"text": "May 12 , 2008 .Senetek issued positive results from a phase I trial of Pyratine-6 for the treatment of acne rosacea .This study enrolled 24 subjects with mild - to - moderate acne rosacea .", "label": "", "metadata": {}, "score": "64.42894"}
{"text": "The primary endpoint was the difference in the mean reduction on the Total Nasal Symptom Score ( TNSS ) observed between the placebo and PreHistin over the fourth , fifth and sixth weeks of the studies .", "label": "", "metadata": {}, "score": "64.54067"}
{"text": "Please refer to The JAMA Network 's Privacy Policy for additional information .Jones PB , Barnes TE , Davies L , et al .Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First - Generation Antipsychotic Drugs in Schizophrenia : Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study ( CUtLASS 1 ) .", "label": "", "metadata": {}, "score": "64.61876"}
{"text": "N Engl J Med 2005;3531209- 1223 PubMed .Figures .Figure 1 .Progress of the randomized patients through the study .FGA indicates first - generation antipsychotic ; SGA , second - generation antipsychotic .", "label": "", "metadata": {}, "score": "64.715576"}
{"text": "Treatment consisted of a topical non - prescription anesthetic for one hour , followed by a one - hour patch application .Overall drug tolerability was good with no safety concerns identified .", "label": "", "metadata": {}, "score": "64.75489"}
{"text": "HIV Neurocognitive Disorders : A Randomized Clinical Trial of CNS - targeted HAART \" is a randomized , controlled clinical trial to assess the efficacy of a strategy for targeting highly active antiretroviral therapy ( HAART ) to the CNS in patients with HIV associated neurocognitive impairment ( HNCI ) .", "label": "", "metadata": {}, "score": "64.77857"}
{"text": "This selection will have been driven by psychiatrist and patient choice , and it supports the applicability of the results to routine clinical practice .Nevertheless , the trial was biased toward schizophrenia that had shown an inadequate response to treatment , an area in which it is most difficult to achieve and demonstrate major change .", "label": "", "metadata": {}, "score": "64.885345"}
{"text": "The specific aims were : .To determine if initial diagnostic work - up with computerized tomography ( CT ) decreases antibiotic use for patients presenting with acute sinusitis symptoms .", "label": "", "metadata": {}, "score": "65.00189"}
{"text": "Treatment was well tolerated , with no serious adverse events reported .Based on the results , Watson plans to file with the FDA for regulatory approval in the second quarter of 2008 .", "label": "", "metadata": {}, "score": "65.13177"}
{"text": "The secondary , per - protocol analysis of 12-week outcomes gave a similar estimate ( Table 4 ) .Differences in Quality of Life Scale ( QLS ) scores at 1 year between patients taking first - generation antipsychotics ( FGAs ) and second - generation antipsychotics ( SGAs ) .", "label": "", "metadata": {}, "score": "65.14595"}
{"text": "75 % of patients receiving COL-3 achieved complete or near complete disappearance of symptoms , as measure by Investigators Global Assessment .Finally , incidence of erythema was slightly improved in the COL-3 group ( 2.5 point reduction in severity ) compared to placebo ( 1.7 point reduction ) .", "label": "", "metadata": {}, "score": "65.15892"}
{"text": "Why did the trial fail to find a clinical advantage for SGAs ?The first possibility is that the proposed effect size of 5 points on the QLS was unrealistically large .", "label": "", "metadata": {}, "score": "65.29404"}
{"text": "This double - blind , placebo - controlled , randomized study enrolled 579 subjects with seasonal allergic rhinitis due to mountain cedar pollen .The subjects were treated for two weeks with various doses of the CRTH2 antagonist or placebo .", "label": "", "metadata": {}, "score": "65.31717"}
{"text": "N Engl J Med 2005;3531209- 1223 PubMed .Correspondence .The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians .", "label": "", "metadata": {}, "score": "65.34123"}
{"text": "The subjects in the Oracea arm had an average of 19.8 inflammatory lesions at baseline and experienced a decrease in lesion count of 12.5 lesions , compared with 17.7 lesions at baseline and a decrease of 12.2 lesions in the doxycycline , 100 mg group .", "label": "", "metadata": {}, "score": "65.43206"}
{"text": "Results showed a significant average increase of more than 250 % in post - treatment blood serum cobalamin ( Vitamin B12 ) levels across the two PreHistin - treated groups compared with essentially no B12 level increase in placebo - treated groups .", "label": "", "metadata": {}, "score": "65.57762"}
{"text": "Based on the results phase III trials are expected to commence shortly .Johnson & Johnson announced positive results from a phase III trial of CNTO1275 for the treatment of psoriasis .", "label": "", "metadata": {}, "score": "65.64425"}
{"text": "Participating psychiatrists used appropriate drug doses in both classes ( Table 2 ) but may have been less ready to change from SGAs in the face of nonresponse during the trial compared with FGAs .", "label": "", "metadata": {}, "score": "65.72761"}
{"text": "It is hypothesized that participants in the CNS - T arm will have greater improvement in neurocognitive functioning than those in the non - CNS - T arm .", "label": "", "metadata": {}, "score": "65.772095"}
{"text": "Research Evidence Summaries .Cascinu , S. , Catalano , V. , Cordella , L. , Labiance , R. , Giordani , P. , Baldelli , A.M. , . . .", "label": "", "metadata": {}, "score": "66.169106"}
{"text": "Data showed a statistically significant delay in time to peak in subjects treated with fluticasone propionate .The open - label , randomized , three - way crossover , inpatient study enrolled 12 subjects with perennial or seasonal rhinitis .", "label": "", "metadata": {}, "score": "66.48497"}
{"text": "March 31 , 2014 .Galderma Laboratories released results of two phase III trials of ivermectin 1 % for the treatment of papulopustular ( inflammatory ) rosacea .", "label": "", "metadata": {}, "score": "66.726395"}
{"text": "An improvement of 5 points in the QLS score resulting from a change in treatment because of adverse effects or lack of effect from previous treatment is a reasonable clinical aim that has also been used in similar trials .", "label": "", "metadata": {}, "score": "66.76447"}
{"text": "Setting Fourteen community psychiatric services in the English National Health Service .Participants Two hundred twenty - seven people aged 18 to 65 years with DSM - IV schizophrenia and related disorders assessed for medication review because of inadequate response or adverse effects .", "label": "", "metadata": {}, "score": "66.76871"}
{"text": "Institution : University of Washington , Seattle Grant Title : Randomized Trial for Sinus CT for Acute Sinusitis Grant Number : K08 HS13613 Duration : 3 years ( 2004 - 2007 ) Total Award : $ 378,200 .", "label": "", "metadata": {}, "score": "66.84105"}
{"text": "After 12 weeks of treatment with ENB-0040 , there were marked improvements in bone mineralization and function , including increases in strength , endurance and mobility and reduction in pain .", "label": "", "metadata": {}, "score": "66.90518"}
{"text": "September 27 , 2010 .GW Pharmaceuticals reported positive results from a phase II trial of Sativex for the treatment of bladder dysfunction related to multiple sclerosis .", "label": "", "metadata": {}, "score": "66.92734"}
{"text": "This randomized , double - blinded , multiple - crossover study enrolled 138 patients with OAB or UUI .Subjects received Tolenix ( 2 mg tolterodine plus 9 mg pilocarpine ) twice daily , or active control Detrol ( 2 mg tolterodine ) twice daily or placebo .", "label": "", "metadata": {}, "score": "67.43427"}
{"text": "Cobalis issued positive final results of a phase III trial of PreHistin , for the treatment of allergic rhinitis .The magnitude of difference in score , 1.31 points , represented a clinically significant difference .", "label": "", "metadata": {}, "score": "67.59122"}
{"text": "If a treatment change was required , the psychiatrist was instructed to initiate an alternative from the same class .Adjunctive medication was allowed , but antipsychotic polypharmacy was discouraged .", "label": "", "metadata": {}, "score": "67.66789"}
{"text": "It will be reviewed by JAMA Psychiatry editors .You will be notified when your comment has been published .Comments should not exceed 500 words of text and 10 references .", "label": "", "metadata": {}, "score": "67.72059"}
{"text": "Enobia released positive interim results from a phase II trial of ENB-0040 for the treatment of hypophosphatasia ( HPP ) .This six - month , randomized , open label , dose comparison study enrolled 13 pediatrics with HPP between the ages of 5 and 12 years across sites in North America .", "label": "", "metadata": {}, "score": "67.80147"}
{"text": "The company announced plans to initiate a second proof - of - principle study , in patients with acne , in the near future .February 23 , 2004 .", "label": "", "metadata": {}, "score": "67.802"}
{"text": "CD07805/47 was shown to be rapidly effective at reducing facial redness and there was no evidence of tachyphylaxis , or rebound .It was safe and well - tolerated .", "label": "", "metadata": {}, "score": "67.9971"}
{"text": "Am J Psychiatry 1997;15499- 105 PubMed .Lewis SWBarnes TREDavies LMurray RMDunn GHayhurst KPMarkwick ALloyd HJones PB Randomized controlled trial of effect of prescription of clozapine versus other second - generation antipsychotic drugs in resistant schizophrenia [ epub ahead of print].", "label": "", "metadata": {}, "score": "68.17403"}
{"text": "Am J Psychiatry 1997;15499- 105 PubMed .Lewis SWBarnes TREDavies LMurray RMDunn GHayhurst KPMarkwick ALloyd HJones PB Randomized controlled trial of effect of prescription of clozapine versus other second - generation antipsychotic drugs in resistant schizophrenia [ epub ahead of print].", "label": "", "metadata": {}, "score": "68.17403"}
{"text": "2 The fact that so few psychiatrists opted for haloperidol in the present trial reflects current clinical practice and inevitably hinders interpretation of the results in the context of existing systematic reviews 3 , 4 of studies using this drug as standard treatment .", "label": "", "metadata": {}, "score": "68.42233"}
{"text": "Exploratory efficacy data indicated that a 100 mcg dose of the drug yielded trends towards reduction in nasal symptoms following ragweed challenge at both 1 and 14 days .", "label": "", "metadata": {}, "score": "68.45148"}
{"text": "Significant difference in the reduction of creatinine clearance for GSH treated group as compared to the control group ( 74 % versus 62 % ) .", "label": "", "metadata": {}, "score": "68.56215"}
{"text": "August 8 , 2005 .CollaGenex issued positive results of a phase II trial of COL-3 , for the treatment of rosacea , at the summer meeting of the North Carolina Dermatology Association .", "label": "", "metadata": {}, "score": "68.804695"}
{"text": "The study met its primary endpoint of improvement in progression - free survival ( PFS ) at the PFS final analysis .Additionally , the study crossed the superiority boundary for overall survival ( OS ) , a key secondary endpoint .", "label": "", "metadata": {}, "score": "68.841705"}
{"text": "The subjects received Sativex or placebo in addition to standard of care for eight weeks .There was no significant effect on incontinence .August 2 , 2010 .", "label": "", "metadata": {}, "score": "68.842285"}
{"text": "The CUtLASS 1 and 2 studies predated the availability of any depot SGA preparations , and trials including these are required .The per - protocol estimate of the treatment effect of the randomized class for the first 3 months of the trial should be interpreted with care because it may be subject to selection biases .", "label": "", "metadata": {}, "score": "69.065994"}
{"text": "The company announced plans to initiate safety and efficacy studies by the end of 2005 or early 2006 .February 9 , 2004 .Intranasal Technology reported results from a clinical trial investigating their intranasal hydromorphone , a narcotic and analgesic for the treatment of allergic rhinitis .", "label": "", "metadata": {}, "score": "69.35803"}
{"text": "A negative parameter estimate means that patients in the FGA arm were doing better ( see the observed means in Table 3 ) .Contrary to the primary hypothesis , the estimate of 5 points in favor of the SGA arm was excluded at the 95 % confidence level .", "label": "", "metadata": {}, "score": "69.39565"}
{"text": "NeurogesX reported positive results from a phase II trial investigating NGX-4010 , a capsaicin - containing dermal patch for the treatment of postherpetic neuralgia ( post - shingles pain ) .", "label": "", "metadata": {}, "score": "69.57175"}
{"text": "Depomed has issued positive results of a pair of trials of gabapentin GR for the treatment of post - herpetic neuralgia ( PHN ) .These open - label studies enrolled 33 healthy male volunteers in a pharmacokinetic study and a dose proportionality study .", "label": "", "metadata": {}, "score": "69.58633"}
{"text": "Subjects achieved an average improvement of 64 meters ( 62 % ) in the 6-minute walk test and an average improvement of 155 meters ( 98 % ) in the 12-minute walk test .", "label": "", "metadata": {}, "score": "69.60262"}
{"text": "October 27 , 2014 .Repros Therapeutics reported results of a phase III study of Androxal ( ZA-303 ) to evaluate the effects on bone mineral density of administration of Androxal for 52 weeks to overweight men with acquired hypogonadotropic hypogonadism .", "label": "", "metadata": {}, "score": "69.64172"}
{"text": "The primary endpoint was the proportion of subjects who achieved a Psoriasis Area and Severity Index ( PASI ) score of 75 at week 12 .", "label": "", "metadata": {}, "score": "69.65959"}
{"text": "There were weekly discussions of ratings within medical centers , monthly intercenter video conferences , and face - to - face intercenter meetings every 3 months where fidelity was discussed .", "label": "", "metadata": {}, "score": "69.689026"}
{"text": "A clear difference in the incidence of adverse events , primarily gastrointestinal reactions , was observed between the treatment groups .Nausea , vomiting , diarrhea and stomach discomfort were observed in 26 % of subjects administered 100 mg of doxycycline versus only 5 % in the Oracea group .", "label": "", "metadata": {}, "score": "69.75689"}
{"text": "April 11 , 2005 .XenoPort has reported positive results of a phase IIa trial of their transported gabapentin prodrug XP13512 , for the treatment of post - herpetic neuralgia ( PHN ) .", "label": "", "metadata": {}, "score": "69.88647"}
{"text": "March 5 , 2012 .AltheRx Pharmaceuticals reported results from a phase II trial of Solabegron for the treatment of overactive bladder ( OAB ) .", "label": "", "metadata": {}, "score": "70.0218"}
{"text": "The efficacy of ENB-0040 was primarily based on improvements in rickets as measured by X - rays .Data showed radiographic improvement of rickets noted as early as six weeks after starting treatment .", "label": "", "metadata": {}, "score": "70.11342"}
{"text": "The subjects were exposed on multiple occasions in an Environmental Exposure Chamber to a high aerosol concentration of a common seasonal allergen to which they were sensitive .", "label": "", "metadata": {}, "score": "70.26473"}
{"text": "Sinus CT did not reduce antibiotic use or affect clinical outcomes .Using a disease specific quality of life measure as an outcome , patients that received antibiotics recovered from sinusitis - related symptoms faster than those who did not receive antibiotics at one week , however , no significant difference in the two weeks outcome was seen .", "label": "", "metadata": {}, "score": "70.31526"}
{"text": "Androxal was well - tolerated .Repros plans to file an NDA for Androxal at the end of 2014 .October 29 , 2012 .Celgene International reported results from a phase III trial of pomalidomide plus low - dose dexamethasone compared to high - dose dexamethasone for multiple myeloma .", "label": "", "metadata": {}, "score": "70.35397"}
{"text": "For the QLS subscales , the intraclass correlation coefficients were 0.98 for interpersonal relations , 0.75 for instrumental role , and 0.99 for intrapsychic foundations .", "label": "", "metadata": {}, "score": "70.37067"}
{"text": "We collected cost information about the use of all services , including hospital inpatient and outpatient services , primary and community care services , and prescribed medications .", "label": "", "metadata": {}, "score": "70.49338"}
{"text": "We estimated the intention - to - treat ( ITT ) effect in the primary analyses .Allowance was made for different patterns of loss to follow - up using multiple imputations , assuming the missing data to be ignorable or missing at random .", "label": "", "metadata": {}, "score": "70.64177"}
{"text": "There were no treatment - related serious AEs .October 24 , 2011 .Galderma issued preliminary results from a phase IIb trial of CD07805/47 for moderate to severe facial erythema associated with rosacea .", "label": "", "metadata": {}, "score": "70.82782"}
{"text": "This additional trial delays the projected BLA filing date until 2006 .Isotechnika reported positive interim results of their phase III SPIRIT trial of ISA247 for the treatment of psoriasis .", "label": "", "metadata": {}, "score": "71.12298"}
{"text": "Results were reported in the January issue of Pharmacotherapy .August 19 , 2002 .Inspire Pharmaceuticals announced positive results of a phase II trial with INS37217 Intranasal , a P2Y2 agonist , for the treatment of perennial allergic rhinitis ( PAR ) .", "label": "", "metadata": {}, "score": "71.24835"}
{"text": "Phase III trials of SNT - MC17 are currently underway .March 13 , 2006 .BioMS Medical has issued positive results of a phase II extension trial of MBP8298 , for the treatment of multiple sclerosis ( MS ) .", "label": "", "metadata": {}, "score": "71.33835"}
{"text": "The mean decline in ALS - Functional Score was 5.27 in the celecoxib / creatine arm , compared to 6.47 in the minocycline / creatine arm , and 5.82 in the historical control group .", "label": "", "metadata": {}, "score": "71.4384"}
{"text": "Renovis announced plans to discontinue development of the drug for PHN , but stated that these data would not affect an ongoing phase II trial of the drug for the treatment of sciatica .", "label": "", "metadata": {}, "score": "71.8681"}
{"text": "Presence of serious illness , including HIV - related opportunistic infections , requiring systemic treatment and/or hospitalization until candidate either completes therapy or is clinically stable on therapy , in the opinion of the investigator , for at least 14 days prior to study entry .", "label": "", "metadata": {}, "score": "72.09349"}
{"text": "HIV Neurocognitive Disorders : A Randomized Clinical Trial of CNS - Targeted HAART .Brief Summary .CIT2 is a strategy for targeting HAART ( Highly Active Antiretroviral Therapy ) to the CNS ( Central Nervous System ) in patients with HIV associated neurocognitive impairment ( HNCI ) .", "label": "", "metadata": {}, "score": "72.23197"}
{"text": "Return to : Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First - Generation Antipsychotic Drugs in Schizophrenia : Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study ( CUtLASS 1 ) .", "label": "", "metadata": {}, "score": "72.578415"}
{"text": "Two systematic reviews 2 , 3 showed that the 2 groups of drugs are generally equivalent in terms of efficacy against positive symptoms , whereas another study 4 found evidence of superiority for SGAs .", "label": "", "metadata": {}, "score": "72.653366"}
{"text": "Interventional .Study Phase .Phase 2 Phase 3 .Study Design ICMJE .Allocation : Randomized Endpoint Classification : Efficacy Study Intervention Model : Parallel Assignment Masking : Single Blind ( Subject ) Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "72.777626"}
{"text": "Corgentech issued positive results of a phase II trial of ALGRX 4975 , for the treatment of elbow tendonitis pain .Efficacy was maintained through week 8 , and a trend for reduced pain score for weeks 2 through 12 was noted .", "label": "", "metadata": {}, "score": "72.98703"}
{"text": "Enobia Pharma reported positive results from a phase II trial of ENB-0040 for the treatment of juvenile hypophosphatasia .This six - month , randomized , open label , dose comparison study enrolled 13 subjects , ages five to 12 years with rickets and gross motor deficits from hypophosphatasia .", "label": "", "metadata": {}, "score": "72.99616"}
{"text": "The subjects received Solabegron ( 50 mg and 125 mg ) or placebo twice daily for eight weeks .Solabegron was safe and well - tolerated .", "label": "", "metadata": {}, "score": "73.04712"}
{"text": "Physicians should claim only the credit commensurate with the extent of their participation in the activity .Physicians who complete the CME course and score at least 80 % correct on the quiz are eligible for AMA PRA Category 1 Credit TM .", "label": "", "metadata": {}, "score": "73.5612"}
{"text": "HIV Infections .Intervention ICMJE .Drug : FDA Approved Antiretroviral Therapy ( see list below ) .Combinations of FDA approved antiretroviral agents : .", "label": "", "metadata": {}, "score": "73.70727"}
{"text": "Subjects received odanacatib 50 mg or placebo once weekly for 24 months .All subjects received vitamin D3 ( 5600IU / week ) and also calcium supplementation , if needed .", "label": "", "metadata": {}, "score": "73.984985"}
{"text": "Use of any immunomodulator ( interferons , interleukins , cyclosporine ) , vaccine , or investigational therapy including dexamethasone within 30 days prior to study entry .", "label": "", "metadata": {}, "score": "74.0158"}
{"text": "All the data suggest that careful prescribing of FGAs , at least in the context of a trial , is not associated with poorer efficacy or a greater adverse effect burden , both of which would translate into lower quality of life in the medium term .", "label": "", "metadata": {}, "score": "74.11326"}
{"text": "Drs Jones , Murray , and Lewis gratefully acknowledge research support from the Stanley Medical Research Institute .Barnes TREEdwards JG The side - effects of antipsychotic drugs , I : neuropsychiatric effects .", "label": "", "metadata": {}, "score": "74.263504"}
{"text": "In addition , amelioration of pain was reported in six of seven patients experiencing pain at baseline .Subcutaneous injections of ENB-0040 were generally well tolerated and no serious adverse events were reported .", "label": "", "metadata": {}, "score": "74.447845"}
{"text": "thrice daily gabapentin , followed by randomization to either 1,200 mg twice daily XP13512 or placebo for 14 days .March 14 , 2005 .Renovis announced the results of a phase II study of REN-1654 , their investigational TNF - alpha release inhibitor for the treatment of post - herpetic neuralgia ( PHN ) .", "label": "", "metadata": {}, "score": "74.47525"}
{"text": "Antipsychotic drug costs accounted for a small proportion of total costs ( 2.1 % in the FGA arm and 3.8 % in the SGA arm ) .", "label": "", "metadata": {}, "score": "74.540794"}
{"text": "September 17 , 2007 .Santhera reported positive results from a clinical trial of SNT - MC17 for the treatment of Friedreich 's Ataxia ( FRDA ) .", "label": "", "metadata": {}, "score": "74.772865"}
{"text": "JAMA 2003;2902693- 2702 PubMed .Lieberman JAStroup TSMcEvoy JPSwartz MSRosenheck RAPerkins DOKeefe RSDavis SMDavis CELebowitz BDSevere JHsiao JKClinical Antipsychotic Trials of Intervention Effectiveness ( CATIE )", "label": "", "metadata": {}, "score": "74.81764"}
{"text": "JAMA 2003;2902693- 2702 PubMed .Lieberman JAStroup TSMcEvoy JPSwartz MSRosenheck RAPerkins DOKeefe RSDavis SMDavis CELebowitz BDSevere JHsiao JKClinical Antipsychotic Trials of Intervention Effectiveness ( CATIE )", "label": "", "metadata": {}, "score": "74.81764"}
{"text": "Cmax ranged from 114.8 ng / mL to 733.4 ng / mL , and mean Tmax ranged from 0.5 to 1.3 hours in these same groups .", "label": "", "metadata": {}, "score": "74.93967"}
{"text": "January 17 , 2011 .Vicept Therapeutics reported positive results from a phase II trial of V-101 , a topical cream for the treatment of Erythematotelangiectatic Rosacea .", "label": "", "metadata": {}, "score": "74.9911"}
{"text": "The the 200 mg and 400 mg FV-100 arms also resulted in a respective 4 % and 14 % reduction in the burden of shingles - associated pain over the first 90 days compared to the valacyclovir arm .", "label": "", "metadata": {}, "score": "75.03648"}
{"text": "The doses of some SGAs have become higher in routine clinical practice than those used in the original preregistration trials .These trials provide benchmark data on adverse effect burden , but this may represent an underestimate .", "label": "", "metadata": {}, "score": "75.15577"}
{"text": "27 , 28 Regarding the latter point , the PANSS total score in CUtLASS 1 accounted for only 30 % of the variance in QLS scores at baseline .", "label": "", "metadata": {}, "score": "75.1584"}
{"text": "Those who received GSH were significantly more able to undertake housekeeping and shopping .Limitations : .The study did not clearly identify what the neurologic examination involved .", "label": "", "metadata": {}, "score": "75.286095"}
{"text": "Preliminary results demonstrated that subjects treated with Periostat showed a continuous improvement during the 16-week study compared with placebo .Data showed that subjects given Periostat had a significantly greater reduction in the number of inflammatory lesions compared with placebo .", "label": "", "metadata": {}, "score": "75.55179"}
{"text": "The primary objective was to determine treatment selection based on which drug combination appeared to slow deterioration in the ALS - Functional Score .Results showed subjects treated with AL-08/celcoxib showed a smaller mean functional decline versus AL-08/minocycline .", "label": "", "metadata": {}, "score": "75.69061"}
{"text": "These findings suggest that NC outcomes of ART may be enhanced by the planned application of an ARV selection and clinical monitoring strategy designed to optimize the treatment of CNS infection .", "label": "", "metadata": {}, "score": "75.77503"}
{"text": "A similar reduction was achieved in a subset of subjects with more severe incontinence .Results also showed that 44 % of subjects in the duloxetine arm reported significant improvement in quality of life , compared to 27 % of those in the placebo arm who gave the same measures of improvement .", "label": "", "metadata": {}, "score": "75.930244"}
{"text": "Variables used to impute missing values included nonmissing QLS and PANSS total scores , study center , reason for referral to study ( poor clinical response or intolerance and adverse effects ) , and whether first episode , current alcohol misuse , and current drug misuse .", "label": "", "metadata": {}, "score": "76.0336"}
{"text": "April 25 , 2005 .CollaGenex announced positive results of a phase II trial of COL-3 , for the treatment of rosacea .Furthermore , improvement was also seen in lesion count during interim observations , overall clinical severity score and incidence of erythema .", "label": "", "metadata": {}, "score": "76.162796"}
{"text": "These data served to support the company 's ongoing phase III development program and eventual NDA submission .September 26 , 2005 .Evolutec has issued positive results of a phase II trial of rEV131 , their recombinant immunomodulatory drug under investigation for the treatment of seasonal allergic rhinitis .", "label": "", "metadata": {}, "score": "76.36164"}
{"text": "TheraVida intends to conduct additional international clinical trials .April 2 , 2012 .Allergan released initial results from two phase III trials evaluating Botox for the treatment of idiopathic overactive bladder ( OAB ) .", "label": "", "metadata": {}, "score": "76.44831"}
{"text": "The within - group standard deviations were as expected .The higher baseline to 12-month correlation implied that the within - group standard deviation for the change score was approximately 13 .", "label": "", "metadata": {}, "score": "76.65669"}
{"text": "A phase III study of MK-8237 in adolescents and adults with house dust mite - induced allergic rhinitis currently is screening patients .May 30 , 2011 .", "label": "", "metadata": {}, "score": "76.81821"}
{"text": "Limitations : .The study is almost 20 years old .Well - described methods and measures recorded higher than expected levels of neurotoxicity in the control arm , but could be from specific attention to the symptom .", "label": "", "metadata": {}, "score": "76.82394"}
{"text": "Neither property has been supported by a systematic review of trials of sulpiride .There were slightly more patients receiving depot preparations before randomization among those allocated to the FGA compared with the SGA group .", "label": "", "metadata": {}, "score": "76.90204"}
{"text": "Secondary endpoints included the change on the International Cooperative Ataxia Rating Scale ( ICARS ) and the Friedreich Ataxia Rating Scale ( FARS ) .The endpoints were achieved , with dose dependent improvements observed in each .", "label": "", "metadata": {}, "score": "76.96617"}
{"text": "Furthermore , alicaforsen produced a 31 % improvement from baseline in terms of plaque induration at both four and eight weeks .Alicaforsen is being developed by Isis Pharmaceuticals .", "label": "", "metadata": {}, "score": "77.07673"}
{"text": "Data from a pooled analysis of two phase III trials indicates that Xanelim ( efalizumab ) produces an early clinical improvement in subjects with moderate - to - severe psoriasis .", "label": "", "metadata": {}, "score": "77.40288"}
{"text": "Table 3 gives the QLS data at each assessment point .Table 4 presents the primary ITT analysis , including imputed values for missing observations , and the secondary per - protocol explorations .", "label": "", "metadata": {}, "score": "77.4335"}
{"text": "It is also hypothesized that although CSF viral suppression will be more frequent in the CNS - T arm , plasma viral suppression will be similar in the two treatment arms .", "label": "", "metadata": {}, "score": "77.667465"}
{"text": "At week 16 , after MetroGel had been discontinued , the subjects on Oracea alone maintained their improvement while those on placebo did not .Oracea was approved by the FDA as a monotherapy treatment of rosacea in May of 2006 .", "label": "", "metadata": {}, "score": "77.800415"}
{"text": "Musculoskeletal Diseases .June 1 , 2015 .Zafgen issued results of a phase II study of beloranib for Prader - Willi syndrome ( PWS ) .", "label": "", "metadata": {}, "score": "77.95927"}
{"text": "Participants reported no clear preference for either drug group ; costs were similar .Conclusions In people with schizophrenia whose medication is changed for clinical reasons , there is no disadvantage across 1 year in terms of quality of life , symptoms , or associated costs of care in using FGAs rather than nonclozapine SGAs .", "label": "", "metadata": {}, "score": "78.20125"}
{"text": "We emphasize that we do not present a null result ; the hypothesis that SGAs are superior was clearly rejected .Third , quality of life is difficult to assess in schizophrenia , and insensitivity and imprecision of the QLS would have reduced power , although similarly in both trial arms .", "label": "", "metadata": {}, "score": "78.302734"}
{"text": "Related Medical Areas .This information does not represent a Lupus Research Institute endorsement of any listed study .It is merely a notice that the study is available .", "label": "", "metadata": {}, "score": "78.560844"}
{"text": "No substantial changes in body temperature were observed at any of the three dose levels administered .XEN - D0501 was safe and well tolerated at doses up to 5 mg twice daily for 14 days .", "label": "", "metadata": {}, "score": "78.64494"}
{"text": "London , England Academic Press1993;213-247 .Bagnall AMJones LGinnelly LLewis RGlanville JGilbody SDavies LTorgerson DKleijnen JA systematic review of atypical antipsychotic drugs in schizophrenia .", "label": "", "metadata": {}, "score": "78.67116"}
{"text": "Neurotoxicity was expressed according to National Cancer Institute Common Terminology Criteria for Adverse Events .Neurophysiologic evaluation of sensory nerve conduction in the sural nerves was performed by the same examiners who were blinded to the group affiliation .", "label": "", "metadata": {}, "score": "78.82612"}
{"text": "In the dose - proportionality study , 19 subjects received escalating single doses of gabapentin GR ( 600 mg , 1200 mg , 1800 mg or 2400 mg ) .", "label": "", "metadata": {}, "score": "78.89742"}
{"text": "GSH was administered at a dose of 1,500 mg / m\u00b2 in 100 ml of normal saline over 15 minutes immediately before each oxaliplatin administration .", "label": "", "metadata": {}, "score": "78.94658"}
{"text": "June 6 , 2005 .Merck and Oka has reported positive results of a phase III trial of Zostavax , their live attenuated Herpes zoster vaccine , for the prevention of shingles .", "label": "", "metadata": {}, "score": "78.95674"}
{"text": "To determine whether sinus CT decreases overall healthcare costs and increases cost - effectiveness for patients with acute sinusitis .Career Goals : Dr. Anzai is a Professor of Radiology and co - Director of the Health Services Research Section of the Department of Radiology at University of Washington .", "label": "", "metadata": {}, "score": "79.00081"}
{"text": "Pharmacokinetic analysis indicated that the prodrug produced a higher absolute steady - state plasma concentration than gabapentin alone , despite a 33 % reduction in total equivalent gabapentin dose .", "label": "", "metadata": {}, "score": "79.47923"}
{"text": "September 15 , 2003 .Eli Lilly and Boehringer Ingelheim reported positive results from a phase III trial investigating duloxetine , a duel reuptake inhibitor for the treatment of stress urinary incontinence ( SUI ) .", "label": "", "metadata": {}, "score": "79.67076"}
{"text": "No .Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects Bone Diseases .July 6 , 2015 .BioMarin Pharmaceutical released results of a phase II study of BMN 111 ( vosoritide ) in children with achondroplasia .", "label": "", "metadata": {}, "score": "79.804634"}
{"text": "Anturol was well tolerated and no serious adverse events related to the treatment were reported .January 14 , 2008 .Watson reported positive results from a phase III trial of oxybutynin topical gel for the treatment of overactive bladder ( OAB ) .", "label": "", "metadata": {}, "score": "79.923676"}
{"text": "Patients with unstable uncontrolled / partially controlled or severe asthma were excluded from the study , as were patients with forced expiratory volume in 1 second ( FEV1 ) .", "label": "", "metadata": {}, "score": "80.08665"}
{"text": "Leucht SBarnes TRKissling WEngel RRCorrell CKane JM Relapse prevention in schizophrenia with new - generation antipsychotics : a systematic review and exploratory meta - analysis of randomized , controlled trials .", "label": "", "metadata": {}, "score": "80.25377"}
{"text": "Leucht SBarnes TRKissling WEngel RRCorrell CKane JM Relapse prevention in schizophrenia with new - generation antipsychotics : a systematic review and exploratory meta - analysis of randomized , controlled trials .", "label": "", "metadata": {}, "score": "80.25377"}
{"text": "Inspire reported negative results from a phase III trial of epinastine nasal spray for the treatment of seasonal allergic rhinitis ( SAR ) .This fourteen - day , randomized , double - blind trial enrolled seven hundred and ninety eight subjects with documented SAR during mountain cedar season in south central Texas .", "label": "", "metadata": {}, "score": "80.371506"}
{"text": "In addition , for both of these measures , all four individual nasal symptom scores of runny nose , nasal congestion , nasal itching and sneezing demonstrated significant improvement versus placebo .", "label": "", "metadata": {}, "score": "80.43965"}
{"text": "Full results will be presented at the Skin Disease Education Foundation 's Phoenix Dermatology Open Seminar on March 21 , 2004 .March 11 , 2002 .", "label": "", "metadata": {}, "score": "80.65817"}
{"text": "Astellas issued results from two phase III trials of mirabegron for the treatment of overactive bladder .One trial was conducted in Europe and Australia and the other trial was conducted in North America .", "label": "", "metadata": {}, "score": "80.85812"}
{"text": "January 17 , 2011 .Ablynx issued positive interim results from an ongoing phase I trial of ALX-0141 , a nanobody under development for the treatment of degenerative bone diseases .", "label": "", "metadata": {}, "score": "81.22064"}
{"text": "Much evidence concerning the relative efficacy of FGAs and SGAs comes from relatively short - term trials ; dropout rates are high , and effects are assessed using symptom ratings rather than broader outcomes .", "label": "", "metadata": {}, "score": "81.34956"}
{"text": "In both studies , ivermectin 1 % showed comparable tolerability and safety to the control group vehicle .In Studies 1 and 2 in the ivermectin 1 % cream group , 4.2 % and 2.6 % of patients , respectively , who reported adverse events ( AEs ) were considered to have AEs related to study treatment .", "label": "", "metadata": {}, "score": "81.761566"}
{"text": "Active Comparator : non - CNS - targeted .Subjects in the non - CNS - T ( Comparison ) arm will be randomized to receive a regimen ( see list of FDA approved antiretrovirals listed below ) designed to suppress plasma Viral Load , but not expected to have targeted CNS penetration .", "label": "", "metadata": {}, "score": "81.87703"}
{"text": "Isolagen announced positive results of a phase III trial of their autologous fibroblast transplant therapy , dubbed the Isolagen Process , for the treatment of dermal contour deformities .", "label": "", "metadata": {}, "score": "81.90522"}
{"text": "Single doses of up to six levels of AEOL 10150(3 , 12 , 30 , 45 , 60 , and 75 mg ) are being administered .", "label": "", "metadata": {}, "score": "81.93169"}
{"text": "Voruganti LCortese LOyewumi LCernovsky ZAwad A Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability , side - effect profile and impact on quality of life .", "label": "", "metadata": {}, "score": "81.9595"}
{"text": "Voruganti LCortese LOyewumi LCernovsky ZAwad A Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability , side - effect profile and impact on quality of life .", "label": "", "metadata": {}, "score": "81.9595"}
{"text": "February 2012 ( final data collection date for primary outcome measure ) .Current Primary Outcome Measures ICMJE ( submitted : March 21 , 2014 ) .", "label": "", "metadata": {}, "score": "82.17952"}
{"text": "Participants reported no clear preference for either class of drug at any stage .The results of this pragmatic randomized trial refute the hypothesis that the use of SGAs is superior to the use of FGAs in terms of quality of life at 1 year .", "label": "", "metadata": {}, "score": "82.2087"}
{"text": "The primary hypothesis was that the use of SGAs would be associated with a clinically significant improvement in quality of life across 1 year compared with the use of FGAs .", "label": "", "metadata": {}, "score": "82.221664"}
{"text": "The Tolenix arm demonstrated statistically significant and clinically meaningful improvements in saliva production and dry mouth side effects , as compared to active control Detrol .", "label": "", "metadata": {}, "score": "82.38755"}
{"text": "National Collaborating Centre for Mental Health , Guidance on the Use of Newer ( Atypical ) Antipsychotic Drugs for the Treatment of Schizophrenia .London , England National Institute for Clinical Excellence2002 ; .", "label": "", "metadata": {}, "score": "82.5681"}
{"text": "National Collaborating Centre for Mental Health , Guidance on the Use of Newer ( Atypical ) Antipsychotic Drugs for the Treatment of Schizophrenia .London , England National Institute for Clinical Excellence2002 ; .", "label": "", "metadata": {}, "score": "82.5681"}
{"text": "Serious weight gain , 32 diabetes mellitus , 33 and hyperlipidemia 34 may all adversely affect quality of life .One observational study 35 supports our result , but there have been few pragmatic , long - term , randomized studies of the clinical effectiveness of FGAs vs SGAs .", "label": "", "metadata": {}, "score": "82.66275"}
{"text": "Voruganti LHeslegrave RAwad AGSeeman MV Quality of life measurement in schizophrenia : reconciling the quest for subjectivity with the question of reliability .Psychol Med 1998;28165- 172 PubMed .", "label": "", "metadata": {}, "score": "82.95623"}
{"text": "Voruganti LHeslegrave RAwad AGSeeman MV Quality of life measurement in schizophrenia : reconciling the quest for subjectivity with the question of reliability .Psychol Med 1998;28165- 172 PubMed .", "label": "", "metadata": {}, "score": "82.95623"}
{"text": "The primary efficacy endpoint was average change from baseline for the reflective Total Nasal Symptom Score ( TNSS ) .The study failed to achieve statistical significance compared to placebo on this endpoint .", "label": "", "metadata": {}, "score": "83.117294"}
{"text": "Table 5 gives the results of the secondary outcomes .The PANSS total scores include imputed values obtained by multiple imputations ; all available data were used for the other outcomes .", "label": "", "metadata": {}, "score": "83.18142"}
{"text": "Patients were excluded if they had established clinical neuropathy , diabetes , alcoholic disease , other neurologic disease or brain involvement .Those who received vitamin B1 , B6 , or B12 supplements also were excluded .", "label": "", "metadata": {}, "score": "83.69825"}
{"text": "BioMarin reported positive results from a phase II trial investigating Aryplase ( recombinant human arylsufatase B ) , an enzyme replacement therapy for the treatment of mucopolysaccharidosis VI ( MPS VI ) .", "label": "", "metadata": {}, "score": "83.75745"}
{"text": "The drug was well tolerated .There were no treatment - related adverse events .December 10 , 2007 .Avicena released positive results from a phase II trial of AL-08 for the treatment of Amyotrophic Lateral Sclerosis ( ALS ) .", "label": "", "metadata": {}, "score": "83.773926"}
{"text": "Tolenix was well tolerated .Based on these data , TheraVida plans to conduct additional international studies of Tolenix in OAB and UUI .January 14 , 2013 .", "label": "", "metadata": {}, "score": "84.066315"}
{"text": "Figures in this Article .Antipsychotic drugs have been the mainstay of schizophrenia treatment for almost 50 years .However , many people with schizophrenia receiving typical or first - generation antipsychotics ( FGAs ) have had a suboptimal outcome , with symptomatic relapses and disabling adverse effects , particularly sedation and extrapyramidal symptoms ( EPSs ) .", "label": "", "metadata": {}, "score": "84.290375"}
{"text": "Subjects received either Tolenix ( 2 mg tolterodine plus 9 mg pilocarpine ) twice daily , Detrol ( tolterodine ) , or placebo .This efficacy was similar in magnitude to the maximum dose of active control Detrol .", "label": "", "metadata": {}, "score": "84.64812"}
{"text": "A positive serum or urine pregnancy test , if female and of reproductive potential .Gender .Both .Ages .18 Years and older .", "label": "", "metadata": {}, "score": "84.82478"}
{"text": "Antipsychotic Drugs and Their Side - Effects .London , England Academic Press1993;213-247 .Bagnall AMJones LGinnelly LLewis RGlanville JGilbody SDavies LTorgerson DKleijnen JA systematic review of atypical antipsychotic drugs in schizophrenia .", "label": "", "metadata": {}, "score": "84.93703"}
{"text": "She specializes in head and neck radiology .Dr. Anzai will continue her independent research with a focus on the development and application of radiological technology , as well as the assessment of the role of such techniques in the health care system .", "label": "", "metadata": {}, "score": "84.956924"}
{"text": "Access to the PDF is only available via article purchase .Shingles .December 20 , 2010 .Inhibitex reported results from a phase II trial of FV-100 for the treatment of shingles .", "label": "", "metadata": {}, "score": "85.259125"}
{"text": "This could lead to an inaccurate conclusion about the benefits of GSH if it delays rather than prevents toxicity .Smyth , J.F. , Bowman , A. , Perren , T. , Wilkinson , P. , Prescott , R.J. , Quinn , K.J. , & Tedeschi , M. ( 1997 ) .", "label": "", "metadata": {}, "score": "85.38028"}
{"text": "October 8 , 2012 .Sarepta Therapeutics released results from a phase IIb trial of eteplirsen for the treatment of Duchenne muscular dystrophy ( DMD ) .", "label": "", "metadata": {}, "score": "85.40271"}
{"text": "Vicept released results from a phase II trial of V-101 for the treatment of erythematous rosacea .This randomized , multi - centered , double - blinded , placebo - controlled trial , V-101-ROSE-206 , enrolled 85 subjects with moderate to severe erythema who received one of two concentrations of V-101 cream or placebo cream .", "label": "", "metadata": {}, "score": "85.4309"}
{"text": "The subjects received four injections of either Pollinex Quattro or placebo treatment over three weeks prior to the 2007 grass pollen season .They then recorded rhino - conjunctivitis symptoms and medication intake over the course of the pollen season from May to September .", "label": "", "metadata": {}, "score": "85.44331"}
{"text": "Willing and able to undergo at least 3 lumbar punctures safely during the course of the study .Potential subjects must have a CD4 cell count obtained within 60 days prior to study entry .", "label": "", "metadata": {}, "score": "85.791"}
{"text": "Most common symptoms included distal parasthesias and numbness in legs , decreased sense of vibration , and reduced or absent deep reflexes .No changes in mean latency and sensory amplitude potentials were noted in the group that received GSH but were significantly affected at 9 and 15 weeks in the control group .", "label": "", "metadata": {}, "score": "85.865654"}
{"text": "Pyratine-6 produced a progressive decrease in the symptoms associated with rosacea including redness and acne lesions .All subject self - assessments showed good tolerability and cosmetic acceptability .", "label": "", "metadata": {}, "score": "85.90046"}
{"text": "American Diabetes Association , American Psychiatric Association , American Association of Clinical Endocrinologists , North American Association for the Study of Obesity , Consensus development conference on antipsychotic drugs and obesity and diabetes .", "label": "", "metadata": {}, "score": "86.17882"}
{"text": "American Diabetes Association , American Psychiatric Association , American Association of Clinical Endocrinologists , North American Association for the Study of Obesity , Consensus development conference on antipsychotic drugs and obesity and diabetes .", "label": "", "metadata": {}, "score": "86.17882"}
{"text": "CI indicates confidence interval .References .Barnes TREEdwards JG The side - effects of antipsychotic drugs , I : neuropsychiatric effects .In : Barnes TREed .", "label": "", "metadata": {}, "score": "86.45125"}
{"text": "Annals of Oncology , 8 , 569 - 573 .Study Purpose : .GSH has high affinity for heavy metals , so the researchers postulated that it may reduce the toxic effects of cisplatin .", "label": "", "metadata": {}, "score": "86.87422"}
{"text": "The exclusion criteria were substance misuse or a medical disorder considered clinically to be the major cause of positive psychotic symptoms and a history of neuroleptic malignant syndrome .", "label": "", "metadata": {}, "score": "87.364395"}
{"text": "November 30 , 2009 .Epiphany BioSciences released positive results from a phase IIb trial of valomaciclovir for the treatment of Herpes Zoster ( shingles ) .", "label": "", "metadata": {}, "score": "87.44"}
{"text": "Presence of active , severe psychiatric disorders ( e.g. , major depression , schizophrenia ) that would interfere with interpretation of the study evaluations or adherence to the study protocol or that might make their participation in the study problematic or unsafe .", "label": "", "metadata": {}, "score": "87.44697"}
{"text": "Main Outcome Measures Quality of Life Scale scores , symptoms , adverse effects , participant satisfaction , and costs of care .Results The primary hypothesis of significant improvement in Quality of Life Scale scores during the year after commencement of SGAs vs FGAs was excluded .", "label": "", "metadata": {}, "score": "87.73714"}
{"text": "BioMarin has announced positive results from a phase III extension study of Aryplase ( galsulfase , rhASB ) , their investigational enzyme replacement therapy for the treatment of mucopolysaccharidosis VI ( MPS VI ) , also called Maroteaux - Lamy Syndrome .", "label": "", "metadata": {}, "score": "88.22484"}
{"text": "Given that any disadvantage for this class may have been due to adverse effects , any resulting bias would have operated against , not for , these drugs .", "label": "", "metadata": {}, "score": "88.36515"}
{"text": "Antares Pharma announced positive results of phase II trial of Anturol ( oxybutynin topical gel ) for the treatment of overactive bladder ( OAB ) .", "label": "", "metadata": {}, "score": "88.887665"}
{"text": "Study results showed that all subjects experienced less urinary leakage while using the FemSoft Insert during exercise activities .Median urine loss was 20 g in women not wearing the device compared to 2.58 g for those using the product .", "label": "", "metadata": {}, "score": "88.96771"}
{"text": "Xanelim is being developed by Genentech and Xoma .Rhinitis , Allergic , Perennial .March 17 , 2014 .Merck released results from phase IIb trials evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet MK-8237 .", "label": "", "metadata": {}, "score": "89.01811"}
{"text": "Celgene has submitted an NDA application to the FDA , as well as an MAA application to the EMA .October 22 , 2012 .Merck issued results from a phase II trial of odanacatib for the treatment of osteoporosis .", "label": "", "metadata": {}, "score": "89.12287"}
{"text": "The treatment was well tolerated across all treatment groups and no serious adverse events were reported .May 9 , 2011 .ISTA Pharmaceuticals issued results from a phase II trial of bepotastine besilate nasal spray for seasonal allergic rhinitis .", "label": "", "metadata": {}, "score": "89.378914"}
{"text": "The primary endpoint was non - inferiority of once - daily valomaciclovir compared to thrice - daily valacyclovir in terms of time to complete crusting of the shingles rash .", "label": "", "metadata": {}, "score": "89.65497"}
{"text": "HNCI is a significant burden to persons living with HIV infection , caregivers , and the healthcare system .Thus the development of effective treatment strategies is of critical public health importance .", "label": "", "metadata": {}, "score": "89.91927"}
{"text": "Norvir .Prezista .Reyataz .Viracept .Fuzeon .Selzentry .Isentress .Study Arm ( s ) .Experimental : CNS - targeted .", "label": "", "metadata": {}, "score": "90.57959"}
{"text": "February 11 , 2002 .Results of a pilot study support the efficacy and safety of FemSoft Insert as a treatment for exercise - induced incontinence .", "label": "", "metadata": {}, "score": "90.62227"}
{"text": "The GDS ranges in value from 0 - 5 ; higher scores indicate poorer cognitive functioning .Subjects with scores greater than or equal to 0.5 are considered cognitively impaired .", "label": "", "metadata": {}, "score": "90.95502"}
{"text": "The first atypical drug , clozapine , is the most efficacious of all antipsychotics but is restricted to treatment - resistant schizophrenia because of adverse effects .", "label": "", "metadata": {}, "score": "91.221535"}
{"text": "Aeolus Pharmaceuticals reported interim results from a phase I trial investigating AEOL 10150 , a antioxidant neuroprotectant under development for the treatment of amyotrophic lateral sclerosis ( ALS or Lou Gehrig 's disease ) .", "label": "", "metadata": {}, "score": "91.24702"}
{"text": "Urinary Incontinence .April 1 , 2013 .TheraVida reported results from a phase II trial of Tolenix ( THVD-201 ) , for the treatment of overactive bladder ( OAB ) and urge urinary incontinence ( UUI ) .", "label": "", "metadata": {}, "score": "91.34833"}
{"text": "In the valacyclovir arm the time to lesion crusting was faster than the FV-100 arms ; however , no differences were noted between the treatment arms on time to full lesion healing .", "label": "", "metadata": {}, "score": "91.442116"}
{"text": "August 9 , 2004 .Lilly and Boehringer - Ingelheim released additional results of a 12 week extension of their phase III study of Yentreve ( duloxetine ) , a dual serotonin / norepinephrine reuptake inhibitor for the treatment of stress urinary incontinence ( SUI ) in women .", "label": "", "metadata": {}, "score": "91.94534"}
{"text": "October 11 , 2010 .ISTA Pharmaceuticals reported positive results from a phase I / II trial of bepotastine besilate nasal spray for the treatment of seasonal allergic rhinitis .", "label": "", "metadata": {}, "score": "92.959114"}
{"text": "Thioridazine hydrochloride and droperidol were also included initially but were withdrawn from licensed use during the trial .The SGAs were risperidone , olanzapine , amisulpride , zotepine , and quetiapine fumarate ( ziprasidone has not been licensed in England ) .", "label": "", "metadata": {}, "score": "92.96167"}
{"text": "Olanzapine treatment was associated with the lowest risk of discontinuation and a different adverse effect profile .The remaining SGAs differed neither from each other in terms of effectiveness nor from perphenazine .", "label": "", "metadata": {}, "score": "93.21028"}
{"text": "The primary outcome is change in global neuropsychological ( NP ) performance , as measured by , change in Global Deficit Score ( GDS ) .", "label": "", "metadata": {}, "score": "93.31996"}
{"text": "The highest two concentrations of bepotatine besilate nasal spray tested showed statistically significant improvement compared to placebo in reducing total nasal symptoms .These reports were consistent for both instantaneous and reflective experiences of their total nasal symptoms .", "label": "", "metadata": {}, "score": "94.05361"}
{"text": "Context Second - generation ( atypical ) antipsychotics ( SGAs ) are more expensive than first - generation ( typical ) antipsychotics ( FGAs ) but are perceived to be more effective , with fewer adverse effects , and preferable to patients .", "label": "", "metadata": {}, "score": "94.36308"}
{"text": "Genzyme has reported interim results of a pivotal trial of Myozyme ( alglucosidase alfa ) , under investigation for the treatment of Pompe disease , a rare hereditary progressive muscle disease .", "label": "", "metadata": {}, "score": "95.01993"}
{"text": "The subjects received one of three concentrations of bepotastine besilate nasal spray or placebo twice a day for two weeks .All three concentrations of bepotastine besilate nasal spray showed statistically significant improvements compared to placebo for nasal and ocular symptoms following exposure to Mountain Cedar pollen during the peak season for this allergen .", "label": "", "metadata": {}, "score": "95.37652"}
{"text": "Corixa has announced positive results of a phase I trial of CRX-675 , their toll - like receptor 4 agonist under investigation for the treatment of allergic rhinitis .", "label": "", "metadata": {}, "score": "95.590866"}
{"text": "The effects of beloranib treatment on body mass and total fat mass in this trial were similar to those seen in non - PWS obese patients , indicating beloranib effects are evident in PWS as well .", "label": "", "metadata": {}, "score": "95.86835"}
{"text": "In addition , 51 % of all subjects taking duloxetine experienced a 50 % to 100 % reduction in frequency of incontinence episodes .Data also showed that women on duloxetine experienced significant improvements in quality of life measures , compared with placebo .", "label": "", "metadata": {}, "score": "96.20183"}
{"text": "Do not contact the Lupus Research Institute for information on these studies .Only contact the listed numbers .The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies , other than to make people aware that they are being conducted .", "label": "", "metadata": {}, "score": "97.70713"}
{"text": "Safety data demonstrated bepotastine besilate was well - tolerated as a nasal spray , with an adverse event profile similar to placebo .February 14 , 2011 .", "label": "", "metadata": {}, "score": "97.927704"}
{"text": "This result is consistent with phase I results which also indicated the most robust effects in the mid - dose group .Glutathione .Glutathione is a peptide that contains one amino acid residue each of glutamic acid , cysteine , and glycine that occurs widely in plant and animal tissues and plays an important role in biologic oxidation - reduction processes and as a coenzyme .", "label": "", "metadata": {}, "score": "98.47308"}
{"text": "Objective To test the hypothesis that in people with schizophrenia requiring a change in treatment , SGAs other than clozapine are associated with improved quality of life across 1 year compared with FGAs .", "label": "", "metadata": {}, "score": "99.478264"}
{"text": "Odanacatib was well tolerated .The most frequent adverse events were urinary tract infection , back pain , arthralgia , fractures , bronchitis , nasal pharyngitis and upper respiratory infection .", "label": "", "metadata": {}, "score": "99.97043"}
{"text": "Despite its name , its pharmacologic features have little in common with amisulpride , an SGA .Anecdotally , sulpiride is sometimes thought to pose a lower risk of EPSs than other FGAs ; this may have been the reason it was chosen relatively frequently .", "label": "", "metadata": {}, "score": "100.06393"}
{"text": "If all authors have none , check \" No potential conflicts or relevant financial interests \" in the box below .Please also indicate any funding received in support of this work .", "label": "", "metadata": {}, "score": "100.88665"}
{"text": "Adverse events were similar across all treatment groups .May 26 , 2008 .Allergy Therapeutics released positive results from a phase III trial of Pollinex Quattro for the treatment of seasonal allergic rhino - conjunctivitis caused by grass allergy .", "label": "", "metadata": {}, "score": "101.61529"}
{"text": "Financial Disclosure : Dr Jones has acted as a consultant to Bristol Myers Squibb , Otsuka , Eli Lilly , and Janssen Cilag .Dr Barnes has acted as a consultant to Servier and Johnson & Johnson Pharmaceutical Services .", "label": "", "metadata": {}, "score": "104.26036"}
{"text": "Melkersson KIHulting ALBrismar KE Elevated levels of insulin , leptin , and blood lipids in olanzapine - treated patients with schizophrenia or related psychoses .J Clin Psychiatry 2000;61742- 749 PubMed .", "label": "", "metadata": {}, "score": "104.50569"}
{"text": "Melkersson KIHulting ALBrismar KE Elevated levels of insulin , leptin , and blood lipids in olanzapine - treated patients with schizophrenia or related psychoses .J Clin Psychiatry 2000;61742- 749 PubMed .", "label": "", "metadata": {}, "score": "104.50569"}
{"text": "Nevertheless , meta - analyses 6 , 7 have raised questions about the size and significance of these effects .Like FGAs , SGAs ( apart from clozapine ) are usually grouped as a class in clinical guidelines , despite pharmacologic heterogeneity . 8 , 9 The SGAs are much more expensive .", "label": "", "metadata": {}, "score": "104.98508"}
{"text": "It was current when produced and may now be outdated .Archive material is no longer maintained , and some links may not work .Persons with disabilities having difficulty accessing this information should contact us at : https://info.ahrq.gov .", "label": "", "metadata": {}, "score": "107.21385"}
{"text": "By using it you agree that that you are requesting the material solely for personal , non - commercial use , and that it is subject to the AMA 's Terms of Use .", "label": "", "metadata": {}, "score": "110.24641"}
{"text": "If your institution uses Athens or Shibboleth authentication , please contact your site administrator to receive your user name and password .What is this ?", "label": "", "metadata": {}, "score": "115.69627"}
{"text": "Only content that has not been published , posted , or submitted elsewhere should be submitted .By submitting this Comment , you and any coauthors transfer copyright to the journal if your Comment is posted .", "label": "", "metadata": {}, "score": "118.68258"}
{"text": "doi:10.1001/archpsyc.63.10.1079 .Athens and Shibboleth are access management services that provide single sign - on to protected resources .They replace the multiple user names and passwords necessary to access subscription - based content with a single user name and password that can be entered once per session .", "label": "", "metadata": {}, "score": "121.377815"}
{"text": "Glutathione is synthesized by the body and is also present naturally in many foods .It is also available as an oral dietary supplement , although not well absorbed when taken by mouth .", "label": "", "metadata": {}, "score": "125.358025"}
